EWEvelyn P. Whitlock

Evelyn P. Whitlock

*This is an algorithmically generated author record based on publicly available information.

Evelyn P. Whitlock has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 June 2016

    Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task Force

    by Jennifer S Lin, Margaret A Piper, Leslie A Perdue, Carolyn Rutter, Elizabeth M Webber, Elizabeth O’Connor, Ning Smith, Evelyn P Whitlock

    We conducted this systematic review to support the U.S. Preventive Services Task Force in updating its recommendation on screening for colorectal cancer (CRC). Our review addresses three questions: 1) What is the effectiveness of screening programs in reducing incidence of and mortality from CRC? 2) What are the test performance characteristics of the different screening tests for detecting CRC, advanced adenomas, and/or adenomatous polyps based on size? and 3) What are the adverse effects of the different screening tests, and do adverse effects vary by important subpopulations? We updated our prior systematic review and searched MEDLINE, PubMed, and the Cochrane Central Register of Controlled Trials to locate relevant studies for all key questions, from the end of our prior review through December 31, 2014. We reviewed 8,492 abstracts and 696 articles against the specified inclusion criteria. We carried an additional 33 studies forward from our prior review. Eligible studies included English-language studies conducted in asymptomatic screening populations age 40 years and older at average risk or unselected for risk factors. We conducted dual independent critical appraisal of all included studies and extracted all important study details and outcomes from fair- or good-quality studies. We synthesized results by key question and type of screening test. We primarily used qualitative synthesis. We used random-effects meta-analyses when appropriate. We also summarized the overall strength of evidence for each key question. KEY QUESTION 1: We included 25 unique fair- to good-quality studies that assessed the effectiveness or comparative effectiveness of screening tests as a single application or in a screening program on CRC incidence and mortality. Based on four randomized, controlled trials (RCTs) (n=458,002), flexible sigmoidoscopy (FS) consistently decreased CRC-specific mortality compared to no screening at 11 to 12 years of followup (incidence rate ratio, 0.73 [95% CI, 0.66 to 0.82]). Based on five RCTs (n=404,396), biennial screening with the guaiac-based fecal occult blood test (Hemoccult II) compared to no screening resulted in reduction of CRC-specific mortality at 11 to 30 years of followup, ranging from 9 to 22 percentage points after two to nine rounds of screening. One prospective cohort (n=88,902) found that the CRC-specific mortality rate was lower at 24 years in persons who self-reported screening with colonoscopy (adjusted hazard ratio, 0.32 [95% CI, 0.24 to 0.45]) compared to those who had never had screening endoscopy. KEY QUESTION 2: We included 33 unique studies evaluating the one-time diagnostic accuracy of various screening tests compared to an adequate reference standard. Only four fair- to good-quality studies (n=4,821) reported the diagnostic accuracy of colonoscopy generalizable to community practice. Based on three studies comparing colonoscopy to CTC or CTC-enhanced colonoscopy (n=2,290), the per-person sensitivity...


  • Validity of diabetes self-reports in the Women’s Health Initiative

    by Jody M. Rn Jackson, Terese A. DeFor, A. Lauren Crain, Tessa J. Mph Kerby, Lori S. MMatSE Strayer, Cora E. Md Lewis, Evelyn P. Whitlock, Selvi B. Williams, Mara Z. DrPH Vitolins, Rebecca J. Rodabough, et al.

    Objective This study aims to determine the positive and negative predictive values of self-reported diabetes during the Women’s Health Initiative (WHI) clinical trials. Methods All WHI trial participants from four field centers who self-reported diabetes at baseline or during follow-up, as well as a random sample of women who did not self-report diabetes, were identified. Women were surveyed regarding diagnosis and treatment. Medical records were obtained and reviewed for documented treatment with antidiabetes medications or for physician diagnosis of diabetes supported by laboratory measurements of glucose. Results We identified 1,275 eligible participants; 732 consented and provided survey data. Medical records were obtained for 715 women (prevalent diabetes, 207; incident diabetes, 325; no diabetes, 183). Records confirmed 91.8% (95% CI, 87.0-95.0) of self-reported prevalent diabetes cases and 82.2% (95% CI, 77.5-86.1) of incident diabetes cases. Among those who never self-reported diabetes, there was no medical record or laboratory evidence for diabetes in 94.5% (95% CI, 89.9-97.2). Women with higher body mass index were more likely to accurately self-report incident diabetes. In a subgroup of participants enrolled in fee-for-service Medicare, a claims algorithm correctly classified nearly all diabetes cases and noncases. Conclusions Among WHI clinical trial participants, there are high positive predictive values of self-reported prevalent diabetes (91.8%) and incident diabetes (82.2%) and a high negative predictive value (94.5%) when diabetes is not reported. For participants enrolled in fee-for-service Medicare, a claims algorithm has high positive and negative predictive values.


  • Open Access

    Integration of existing systematic reviews into new reviews: identification of guidance needs

    by Karen A Robinson, Evelyn P Whitlock, Maya E Oneil, Johanna K Anderson, Lisa Hartling, Donna M Dryden, Mary Butler, Sydne J Newberry, Melissa McPheeters, Nancy D Berkman, et al.

    An exponential increase in the number of systematic reviews published, and constrained resources for new reviews, means that there is an urgent need for guidance on explicitly and transparently integrating existing reviews into new systematic reviews. The objectives of this paper are: 1) to identify areas where existing guidance may be adopted or adapted, and 2) to suggest areas for future guidance development. We searched documents and websites from healthcare focused systematic review organizations to identify and, where available, to summarize relevant guidance on the use of existing systematic reviews. We conducted informational interviews with members of Evidence-based Practice Centers (EPCs) to gather experiences in integrating existing systematic reviews, including common issues and challenges, as well as potential solutions. There was consensus among systematic review organizations and the EPCs about some aspects of incorporating existing systematic reviews into new reviews. Current guidance may be used in assessing the relevance of prior reviews and in scanning references of prior reviews to identify studies for a new review. However, areas of challenge remain. Areas in need of guidance include how to synthesize, grade the strength of, and present bodies of evidence composed of primary studies and existing systematic reviews. For instance, empiric evidence is needed regarding how to quality check data abstraction and when and how to use study-level risk of bias assessments from prior reviews. There remain areas of uncertainty for how to integrate existing systematic reviews into new reviews. Methods research and consensus processes among systematic review organizations are needed to develop guidance to address these challenges.


  • Comparative Effectiveness Topics from a Large, Integrated Delivery System

    by Kim N Danforth, Carrie D Patnode, Tanya J Kapka, Melissa G Butler, Bernadette Collins, Amy Compton-Phillips, Raymond J Baxter, Jed Weissberg, Elizabeth A McGlynn, Evelyn P Whitlock

    To identify high-priority comparative effectiveness questions directly relevant to care delivery in a large, US integrated health care system. In 2010, a total of 792 clinical and operational leaders in Kaiser Permanente were sent an electronic survey requesting nominations of comparative effectiveness research questions; most recipients (83%) had direct clinical roles. Nominated questions were divided into 18 surveys of related topics that included 9 to 23 questions for prioritization. The next year, 648 recipients were electronically sent 1 of the 18 surveys to prioritize nominated questions. Surveys were assigned to recipients on the basis of their nominations or specialty. High-priority questions were identified by comparing the frequency a question was selected to an "expected" frequency, calculated to account for the varying number of questions and respondents across prioritization surveys. High-priority questions were those selected more frequently than expected. More than 320 research questions were nominated from 181 individuals. Questions most frequently addressed cardiovascular and peripheral vascular disease; obesity, diabetes, endocrinology, and metabolic disorders; or service delivery and systems-level questions. Ninety-five high-priority research questions were identified, encompassing a wide range of health questions that ranged from prevention and screening to treatment and quality of life. Many were complex questions from a systems perspective regarding how to deliver the best care. The 95 questions identified and prioritized by leaders on the front lines of health care delivery may inform the national discussion regarding comparative effectiveness research. Additionally, our experience provides insight in engaging real-world stakeholders in setting a health care research agenda.


    • 1 September 2013

    The Ankle Brachial Index for Peripheral Artery Disease Screening and Cardiovascular Disease Prediction in Asymptomatic Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force

    by Jennifer S Lin, Carin M Olson, Eric S Johnson, Caitlyn A Senger, Clara B Soh, Evelyn P Whitlock

    We conducted a systematic evidence review on the diagnostic and prognostic value of the resting ankle-brachial index (ABI) in unselected populations. This review also examined the benefit and harms of treating generally asymptomatic persons with peripheral artery disease (PAD). We conducted this review to support the U.S. Preventive Services Task Force in updating its recommendation on screening for PAD. We searched MEDLINE and the Cochrane Central Registry of Controlled Trials from 1996 through September 2012 to locate relevant English-language studies. We supplemented these searches with suggestions from experts' reference lists from 62 related systematic reviews. Two investigators independently reviewed 4,434 abstracts and 418 articles against the specified inclusion criteria for diagnostic accuracy studies, prognostic studies, and treatment studies. Our review focused on the utility of using the ABI as a screening or prognostic tool in asymptomatic persons. We excluded populations with symptomatic PAD or known cardiovascular disease (CVD), diabetes, or severe chronic kidney disease. We included diagnostic accuracy studies that evaluated ABI against a reference standard. We included risk prediction studies that evaluated ABI's ability to predict future coronary artery disease (CAD) or CVD events in addition to the Framingham risk score (FRS). Treatment studies were limited to trials evaluating interventions to reduce CVD or maintain lower extremity function. We excluded interventions aimed primarily at management of lower extremity symptoms. We extracted all relevant study details (pertaining to population/setting, diagnostic test or intervention, reference standard or comparator, followup and outcomes), which varied by key question. Diagnostic accuracy studies had outcomes focused on measures of test performance (i.e., sensitivity and specificity). For risk prediction studies, outcomes focused on measures of risk reclassification (i.e., number reclassified, net reclassification index [NRI]), measures of discrimination (i.e., differences in the area under the curve [AUC]), or associations of risk adjusted for FRS predictors (i.e., hazard or risk ratios). We extracted any reported outcomes for treatment trials, including adverse effects. We independently appraised all articles for quality and excluded poor-quality studies. Screening : In one fair-quality study (n=306) in older Swedish adults, the sensitivity of ABI (≤0.9) was low (15% to 20%) but specificity was near 100 percent, and the positive and negative predictive values for ABI were greater than 80 percent. Other diagnostic studies of ABI were primarily conducted in persons referred for vascular testing or with symptoms.Risk prediction: From multiple population cohort studies (18 cohorts; n=52,510), low ABI (≤0.9) was generally associated with future CAD and CVD events, independent of FRS factors. The clinical relevance of the association of a low ABI (≤0.9) and the impact on...


  • Open Access

    Evaluating genomic tests from bench to bedside: a practical framework

    by Jennifer S Lin, Matthew Thompson, Katrina AB Goddard, Margaret A Piper, Carl Heneghan, Evelyn P Whitlock

    The development of genomic tests is one of the most significant technological advances in medical testing in recent decades. As these tests become increasingly available, so does the need for a pragmatic framework to evaluate the evidence base and evidence gaps in order to facilitate informed decision-making. In this article we describe such a framework that can provide a common language and benchmarks for different stakeholders of genomic testing. Each stakeholder can use this framework to specify their respective thresholds for decision-making, depending on their perspective and particular needs. This framework is applicable across a broad range of test applications and can be helpful in the application and communication of a regulatory science for genomic testing. Our framework builds upon existing work and incorporates principles familiar to researchers involved in medical testing (both diagnostic and prognostic) generally, as well as those involved in genomic testing. This framework is organized around six phases in the development of genomic tests beginning with marker identification and ending with population impact, and highlights the important knowledge gaps that need to be filled in establishing the clinical relevance of a test. Our framework focuses on the clinical appropriateness of the four main dimensions of test research questions (population/setting, intervention/index test, comparators/reference test, and outcomes) rather than prescribing a hierarchy of study designs that should be used to address each phase.


    • 1 December 2010

    Behavioral Counseling to Promote Physical Activity and a Healthful Diet to Prevent Cardiovascular Disease in Adults: Update of the Evidence for the U.S. Preventive Services Task Force

    by Jennifer S Lin, Elizabeth O’Connor, Evelyn P Whitlock, Tracy L Beil, Sarah P Zuber, Leslie A Perdue, Daphne Plaut, Kevin Lutz

    We conducted this systematic evidence review of trials of physical activity and/or dietary counseling to prevent cardiovascular disease (CVD) to assist the U.S. Preventive Services Task Force (USPSTF) in updating its 2002 and 2003 recommendations on counseling to improve physical activity and diet, respectively. We searched MEDLINE, PsycInfo, and the Cochrane Central Register of Controlled Trials 2001–2009 to locate relevant trials for all key questions published since the previous reviews were conducted. We supplemented our searches with suggestions from experts and reference lists from other publications, including the prior USPSTF reviews and other relevant systematic reviews. Two investigators independently reviewed 13,562 abstracts and 474 articles against a set of a priori inclusion criteria, and also independently critically appraised each study using design-specific quality criteria based on USPSTF methods. Discrepancies were resolved by consensus. In total, 109 articles representing 73 unique studies were included. One investigator abstracted data from included studies into evidence tables and a second reviewer checked these data. We conducted meta-analyses on 58 trials that provided necessary data to estimate the effect size of counseling on both intermediate health outcomes (adiposity, systolic and diastolic blood pressure, total cholesterol, high-density lipoproteins [HDLs], low-density lipoproteins [LDLs], triglycerides, and glucose) and behavioral outcomes (self-reported physical activity; fitness; intake of total energy, fat, saturated fat, fiber, fruits and vegetables; and urinary sodium as a measure of sodium intake). Key Question 1: Do healthful diet and/or physical activity interventions improve CVD health outcomes in adults? One large, good-quality trial evaluating an intensive healthful diet counseling intervention showed no difference in the incidence of coronary heart disease or stroke over a mean of 8 years followup. Observational followup of two hypertension prevention trials evaluating intensive sodium reduction counseling showed a decrease in the incidence of CVD outcomes over 10 to 15 years of followup. Key Question 2: Do healthful diet and/or physical activity interventions improve intermediate outcomes associated with CVD in adults? Medium- (31 to 360 minutes) to high-intensity (>360 minutes) dietary interventions (with or without concomitant physical activity counseling) decreased body mass index (BMI) approximately 0.3 to 0.7 kg/m2 at 12 months. The largest reduction in blood pressures occurred in three intensive salt-restriction counseling interventions in persons with mildly elevated diastolic blood pressure, resulting in approximately 1.8 mmHg lower systolic blood pressure and 1.1 mmHg lower diastolic blood pressure at 12 months. Medium- and high-intensity diet and lifestyle interventions decreased systolic blood pressure by 0.9 to 1.4 mmHg and diastolic blood pressure by 0.7 mmHg. Medium- and...

  • Effectiveness of Weight Management Interventions in Children: A Targeted Systematic Review for the USPSTF

    by Evelyn P. Whitlock, Elizabeth A. O'COnnor, Selvi B. Williams, Tracy L. Beil, Kevin W. Lutz

    CONTEXT: Targeted systematic review to support the updated US Preventive Services Task Force (USPSTF) recommendation on screening for obesity in children and adolescents.OBJECTIVES: To examine the benefits and harms of behavioral and pharmacologic weight-management interventions for overweight and obese children and adolescents.METHODS: Our data sources were Ovid Medline, PsycINFO, the Education Resources Information Center, the Database of Abstracts of Reviews of Effects, the Cochrane databases, reference lists of other reviews and trials, and expert recommendations. After 2 investigators reviewed 2786 abstracts and 369 articles against inclusion/exclusion criteria, we included 15 fair- to good-quality trials in which the effects of treatment on weight, weight-related comorbidities, and harms were evaluated. Studies were quality rated by 2 investigators using established criteria. Investigators abstracted data into standard evidence tables.RESULTS: In the available research, obese (or overweight) children and adolescents aged 4 to 18 years were enrolled, and no studies targeted those younger than 4 years. Comprehensive behavioral interventions of medium-to-high intensity were the most effective behavioral approach with 1.9 to 3.3 kg/m2 difference favoring intervention groups at 12 months. More limited evidence suggests that these improvements can be maintained over the 12 months after the end of treatments and that there are few harms with behavioral interventions. Two medications combined with behavioral interventions resulted in small (0.85 kg/m2 for orlistat) or moderate (2.6 kg/m2 for sibutramine) BMI reduction in obese adolescents on active medication; however, no studies followed weight changes after medication use ended. Potential adverse effects were greater than for behavioral interventions alone and varied in severity. Only 1 medication (orlistat) has been approved by the US Food and Drug Administration for prescription use in those aged ≥12 years.CONCLUSIONS: Over the past several years, research into weight management in obese children and adolescents has improved in quality and quantity. Despite important gaps, available research supports at least short-term benefits of comprehensive medium- to high-intensity behavioral interventions in obese children and adolescents.


    • 1 October 2008

    Screening for Colorectal Cancer: An Updated Systematic Review

    by Evelyn P Whitlock, Jennifer Lin, Elizabeth Liles, Tracy Beil, Rongwei Fu, Elizabeth O'connor, Rebecca Newton Thompson, Taryn Cardenas

    We conducted a systematic review of five key questions to assist the U.S. Preventive Services Task Force (USPSTF) in updating its 2002 recommendation for colorectal cancer (CRC) screening in average-risk adults aged 50 years or older using home fecal occult blood testing (FOBT), flexible sigmoidoscopy (FS), FS and FOBT, colonoscopy, or double-contrast barium enema (DCBE). Key questions for this updated review primarily focused on evidence gaps from the previous review: 1) the accuracy (one-time test performance characteristics) and potential harms of newer CRC screening tests—fecal immunochemical tests (FIT), high-sensitivity FOBT, fecal DNA testing, and CT colonography (CTC)—as possible substitutes for currently recommended CRC screening modalities; 2) updating of evidence on the impact of CRC screening on mortality and to estimate the accuracy and harms of colonoscopy and FS in the community setting. A concurrent decision analysis done by others addressed screening program performance, and compared the life-years gained using different CRC screening tests, test intervals, and stopping ages. We conducted five literature searches of MEDLINE and the Cochrane Library through January 2008. We identified 3948 abstracts from these searches and 488 articles identified from literature searches and outside sources, which we reviewed against specified inclusion-exclusion criteria. Articles were also excluded for quality reasons. Two reviewers' assents were required to exclude a study. One investigator abstracted key elements of all included studies into standardized evidence tables. A second reviewer verified these data. Two investigators critically appraised and quality-rated all studies. Disagreements were resolved by consensus. We reported quantitative synthesis for results of each key question, where possible, and qualitative synthesis otherwise. Impact of Screening on CRC Mortality. We found no new studies of CRC screening that report mortality outcomes; longer-term follow-up of four biennial FOBT screening trials indicates CRC mortality was reduced 13 to 21 percent after 8 to 13 years of screening in two trials, although another two trials did not show mortality benefit until after 15 to18 years of screening. The Cochrane Collaboration's pooled estimate of CRC mortality reduction in all four FOBT trials at last follow-up was 15 percent, using either random or fixed-effect models (RR 0.85, CI: 0.78,0.92). FITs, HemeSensa, fecal DNA. The largest body of evidence to evaluate screening test performance of newer fecal tests in average-risk screening populations is for fecal immunochemical tests (FITs), which cannot be analyzed as a class, but as individual assay types. Specifically, four individual FITs (Magstream/HemeSelect; FlexSure OBT/Hemoccult ICT; OC-Hemodia; Monohaem) have higher sensitivity for CRC (61 to 91 percent) than estimates for nonrehydrated Hemoccult II (25 to 38 percent) from another recent systematic review, with somewhat...